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ABSTRACT 
Objective: Tylvalosin, is a new macrolide antibiotic, it is highly effective against a range of important diseases in many different veterinary species 
specially pigs and poultry. The pharmacokinetics and bioavailability of Tylvalosin were investigated in healthy turkeys.  
Methods: Tylvalosin was orally, intramuscularly, and intravenously administrated to turkeys in a single dose of (25 mg/kg b.w.), and the blood 
samples were analyzed by using a microbiological assay method. 
Results: After intravenous injection, the serum concentration-time curves were best described by a two compartment-open model. The distribution 
and elimination half–life t 0.5 α and t 0.5 β were (0.076±0.0014 h, 0.788±0.107 h), respectively. The volume of distribution Vdss was (1.155±0.183 
L/kg), with body clearance Cl (B) of (1.489±0.143 ml/kg/h). Following oral administration, Tylvalosin was absorbed with t 0.5 ab (0.283±0.012 h) and 
eliminated, with t 0.5 el (5.309±0.542 h). The peak serum concentration was (0.637±0.018 µg/ml) at Tmax of (1.293±0.024 h). Following intramuscular 
administration, Tylvalosin was absorbed with t 0.5 ab (0.076±0.003 h) and eliminated with t 0.5 el (0.467±0.058 h). The peak serum concentration was 
(1.446±0.121 µg/ml) at Tmax of (0.282±0.008 h). The systemic bioavailability of Tylvalosin following oral administration was 33.84% and 14.06% 
after intramuscular administration. 
Conclusion: These results indicate that, after oral and intramuscular administration, Tylvalosin was rapidly absorbed and distributed to tissues of 
turkeys. However, repeated doses are necessary to maintain Tylvalosin serum concentration above the MIC for most susceptible microorganisms.  
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INTRODUCTION 
In turkeys, bacterial infections of the respiratory tract are more 
common and frequently result in economic losses due to increased 
mortality and feed conversion rates, reduced growth and high 
medical costs [1]. Macrolides are widely used antibiotics in 
veterinary medicine due to their ability to accumulate in the 
respiratory tract [2]. 
Tylvalosin is a new macrolide antibiotic. It is previously known as 
(acetyl isovaleryl Tylosin). It derived from fermentation of factor A 
Tylosin with Streptomyces thermotolerans. This fermentation results 
in the acetylation of the highly active 16-member lactone ring [3]. 
Tylvalosin has antibacterial activity against Gram-positive (e.g. 
Staphylococcus, Micrococcus, Microbacterium, Bacillus, Coryne-
bacterium, Aerococcus, Arthrobacter and Streptococcus, 
Campylobacter, Enterococcus and Clostridia) and some Gram-
negative organisms and against mycoplasma by way of inhibition of 
protein synthesis in the bacteria cell by reversibly binding to the 50S 
ribosome subunit. It was not active against most of the gram-
negative strains (including Escherichia coli, Serratia, Klebsiella, 
Proteus, Salmonella, Shigella and Pseudomonas). It is highly effective 
against a range of important diseases in many different veterinary 
species especially pigs and poultry [4]. It indicated for prevention 
and treatment of Mycoplasmosis (Mycoplasma gallisepticum, M. 
synoviae and other Mycoplasma species), Ornithobacterium 
rhinotracheale and for diseases associated with Clostridium 
perfringens in chickens, replacement pullets and turkeys. In addition 
to its direct antimicrobial effect, Tylvalosin exhibits anti-
inflammatory property [5]. 
The pharmacokinetics (PK) behavior of Tylvalosin has been studied 
in chickens after oral administration [6]. However, few 
pharmacokinetics studies of macrolides in turkeys and no data are 
available for Tylvalosin pharmacokinetics in turkeys, so the aim of 
the work was to study the pharmacokinetic aspects of Tylvalosin 
and its bioavailability after oral, intramuscular and intravenous 
administration in turkeys. 
MATERIALS AND METHODS 
Drug 
Aivlosin ® is a veterinary medicinal product containing the 
macrolide antibiotic Tylvalosin (previous name: acetyl iso-valeryl 
tylosin). The drug obtained from (ECO Animal Health, London, UK), 
it is a water-soluble powder and contains 625 mg/g Tylvalosin (as 
Tylvalosin tartrate) as the active substance. 
Turkeys 
The study was carried out on 15 turkeys with an average body 
weight from 1.500 to 1.900 kg and 2 mo old. These birds were 
obtained from a governmental turkey's farm in Beni-Suef 
Governorate. The turkeys were fed on commercial balanced ration 
and water ad-libitum. They were treated in accordance with the 
Guidelines for Animal Experimentation (of the Ethics Review 
Committee) of the Faculty of Veterinary Medicine, Beni-Suef 
University. Turkeys were left without treatment for 15 d before the 
experiment for acclimatization and ensuring complete clearance of 
any antibacterial drugs. 
Experimental design  
Fifteen clinically healthy turkeys were given Tylvalosin 25 mg/kg 
b.w. according to (ECO Animal Health company instruction) and 
classified into three groups (5 each), the 1st group was given a single 
intravenous dose (through wing vein), the 2nd group given a single 
intramuscular dose (thigh muscle) and the 3rd group given a single 
oral dose (intra-crop route). A crossover design was used, with two 
weeks washout period between each route. Blood samples (1.5 ml 
each) were taken from the wing vein just after 5, 10, 15, 30 min, 1, 2, 
4, 6, 8, 12 and 24 h post drug administration. All blood samples were 
left to clot for 30 min, centrifuged at 3000 r. p. m. for 15 min and the 
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obtained clear serum was transferred to eppendorff 's tubes and 
kept in the deep freeze (-20 oC) till assayed. 
Assay for tylvalosin 
Tylvalosin concentrations in serum were determined by 
microbiological assay method [7] and Micrococcus luteus ATCC 9341 
as tested organism [8]. Standard curves of Tylvalosin in turkeys 
were linear over the range of 0.195-50 µg/ml. The diameter of the 
inhibition zones (mm) were linear when plotted against of 
concentration of Tylvalosin (µg/ml) with a correlation coefficient of 
0.998 in normal turkey's serum, 0.994 in distilled water. Estimation 
of protein binding tendency of Tylvalosin was carried by preparing a 
standard solution in distilled water and also in normal antibiotic free 
turkey's serum at concentrations of Tylvalosin 0.195, 0.39, 0.78, 
(reference concentration) 1.56, 3.125, 6.25, 12.5, 25, 50 µg/ml. The 
difference in the diameter of inhibition between the solutions of the 
drugs in the distilled water (buffer) and that in the serum of the 
turkeys was used to calculate the percentage of protein binding of 
the tested antibacterial according to the following equation [9]. 
 
Pharmacokinetic analysis 
Serum concentrations of Tylvalosin versus time curve were 
generated, and best fitted by the aid of computer poly-exponential 
curve stripping program, (R-Strip Micromath, software, USA). Data 
from each chicken was fitted individually, and the pharmacokinetic 
variables were computed by the aid of the software programs. The 
hybrid rate constants of the distribution and elimination phase (α 
and β), and the first order absorption and elimination rate constants 
(K ab and Kel) and corresponding extrapolated zero time intercepts 
(A and B), absorption, distribution and elimination half-lives (t 0.5 ab, t 
0.5 α, t 0.5 β, t 0.5 el), transfer rate constants (K12 and K21). The area under 
the curve from zero to infinite time (AUC 0-œ), mean residence time 
(MRT), maximum serum concentration (Cmax) and time to be 
achieved (Tmax) were calculated. The other pharmacokinetic 
parameters as total body clearance Cl(B), the volume of the central 
compartment (Vc), the volume of distribution at steady state (Vdss) 
and the bioavailability (F) were calculated by standard methods 
[10]. The results were expressed as mean±SE and the obtained data 
statistically using Student ”t” test as described by [11]. 
RESULTS 
After intravenous injection 
The mean serum concentration of Tylvalosin was measured in 
healthy turkeys following a single intravenous dose of 25 mg/kg b.w. 
was (63.33±5.84) and presented in (table 1). The serum drug 
concentrations declined in a biphasic pattern that can be described 
by a two-compartment open model (fig. 1). The pharmacokinetic 
analysis of serum concentration versus time plot after single 
intravenous injection of Tylvalosin was presented in (table 2). It was 
shown that the drug was rapidly distributed with a distribution half-
life (t 0.5 α) of 0.076±0.0014 min. The mean elimination half-life (t 0.5 β) 
was 0.788±0.107 h and the total body clearance of the drug (CLB) 
was 1.489±0.143 ml/kg/h. The apparent volume of distribution (Vc) 
of Tylvalosin in the central compartment showed a significant low 
value (0.406±0.04 L/kg) as compared with the apparent volume of 
distribution of the peripheral compartment (Vd B) of (2.56±0.40 
L/kg) and the total volume of distribution at the steady state (Vdss) 
(1.155±0.183 L/kg). 
After oral administration 
The mean serum concentrations of Tylvalosin at different time 
intervals following a single oral administration of 25 mg/kg b.w. in 
turkeys were presented in (table 1) and depicted in (fig. 1). The drug 
was firstly detected (0.2362±0.016 µg/ml) after 10 min. The 
pharmacokinetic parameters of Tylvalosin following its oral 
administration are tabulated in (table 3). The peak concentration 
(Cmax) was (0.637±0.018 µg/ml) and the calculated value of Tmax was 
(1.293±0.024 h). The drug was absorbed from healthy turkey gut 
with absorption half-life (t 0.5 ab) of 0.283±0.012 hour and eliminated 
with a mean half-life (t 0.5 el) of 5.309±0.542 hour. The calculated 
bioavailability (F %) of Tylvalosin following its single oral 
administration of 25 mg/kg b.w. in turkey was (33.84%±1.864 %). 
After intramuscular injection 
The mean serum concentrations of Tylvalosin at different time 
intervals following a single intramuscular injection of 25 mg/kg b.w. 
in turkeys were presented in (table 1), and depicted in (fig. 1). The 
drug was firstly detected (0.665±0.055 µg/ml) after 5 min. The 
pharmacokinetic parameters of Tylvalosin following its 
intramuscular injection were tabulated in (table 3). Tylvalosin was 
rapidly absorbed after intramuscular administration with 
absorption half-life (t 0.5 ab) 0.076±0.003 h. Peak serum concentration 
(Cmax) was (1.446±0.121 µg/ml) achieved after maximum time (Tmax) 
of (0.282±0.008 h) post administration. The drug was highly 
eliminated from blood with a mean half-life (t 0.5 el) of (0.467±0.0.58 
h). The systemic bioavailability of Tylvalosin after intramuscular 
injection was (14.06±0.69 %). 
Protein binding percent 
The extent of serum protein binding was (12.33±0.489) %. 
DISCUSSION 
Tylvalosin is a recently approved macrolide antibiotic used in 
veterinary medicine with proven efficacy for controlling respiratory 
infection in poultry. To identify the disposition of Tylvalosin in 
turkeys, a pharmacokinetic study of Tylvalosin after oral, 
intramuscular and intravenous administration was performed. 
After a single intravenous injection of Tylvalosin (25 mg/kg b.w.), 
the serum concentration-time curve was best described by a two–
compartment open model [12].  
The drug was rapidly distributed with a distribution half-life of (t 0.5 
α) of (0.076 h). The rapid distribution of Tylvalosin may be due to 
increased tissue distribution, similar to that reported for tylosin 
phosphate and tylosin tartrate in chickens (0.07, 0.09 h), 
respectively [13].  
Tylvalosin was distributed in the central compartment with a 
volume of distribution (Vc = average of 0.406 L/kg) and volume of 
distribution at steady state (Vd ss =1.155 L/kg), this increase of Vd ss 
over Vc indicated that the peripheral compartment is the major 
compartment for Tylvalosin distribution at steady state [14]. Our 
result of Vd ss was similar to the result of tylosin phosphate and 
tylosin tartrate in chickens (1.09, 0.94 L/kg), respectively [13] and in 
pigs (1.4 L/kg) [15], while it was slightly higher than those 
previously reported for broiler chickens (0.69 L/kg) [16]. Tissue 
macrolide concentrations (peripheral compartment) are 
consistently higher than serum (central) concentrations, and peak 
organ tissue concentrations may be as much as five to 10 times 
serum concentrations [17]. This difference in the kinetic parameters 
is due to changes in the chemical structure of Tylvalosin than tylosin. 
In vitro studies have clearly shown Tylvalosin to enter and 
accumulate inside several cell types, including gut epithelial cells, 
whereas tylosin penetration in all cell types is relatively poor [18]. 
The volume of distribution at steady-state Vd ss, Vd B and Vd area 
recorded in our study were more than unity (>one L/kg) following 
intravenous dosage in turkeys, indicating more clearly that the drug 
was widely distributed in the extravascular tissues than in serum. 
These results were supported by [19, 20].  
Tylvalosin was rapidly eliminated with an elimination half-life of (t 
0.5 β) of (0.788 h), our result was nearly similar with finding reported 
for tylosin in broiler chickens (0.52 h) [16], but it was slightly lower 
than reported in chickens (1.04-1.16 h) [13], (1.99-2.67 h) [21] and 
(0.9) in dog [22].  
The rate of clearance in the present study (CL (B) =1.489 ml/kg/h) 
was similar to those reported for tylosin phosphate, tylosin tartrate 
in chickens (1.71-1.61 ml/kg/h), [13] but higher than reported in 
chickens (5.30 ml/kg/min=0.088 ml/kg/h) [16]. Differences in the 
kinetic parameters are relatively common and frequently related to 
interspecies variation, age, breed, health status of the animals 
and/or the assay method used [23].  
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Following a single oral administration of Tylvalosin (25 mg/kg b.w.) 
in normal turkeys, the drug was detected in serum 10 min post 
administration 0.236 µg/ml. It was continued to increase gradually 
thereafter to reach its maximum concentration (C max) 0.637 µg/ml 
at Tmax of 1.293 h post-administration. This result (Cmax) was lower 
than recorded for Tylvalosin in chickens (1.64 µg/ml) by [6]. The 
lower Cmax may be due to the presence of the microbial flora in the 
crop, which could inactivate macrolides [24]. 
The present study showed that Tylvalosin was rapidly absorbed and 
widely distributed to tissues indicated by low absorption rate 
constant (kab) and absorption half-life (t 0.5 ab) 0.283 h, this result was 
similar to that obtained in chickens (0.175, 0.471 h) when used 
flexible and rigid catheter, respectively [6, 4]. The pharmacokinetics 
of Tylvalosin in chickens showed a high variation in the absorption 
profile not only between individuals but also within individuals when 
used on separate occasions [6]. The absorption may be decreased a 
consequence of the presence of food in the crop or due to the presence 
of Lactobacillus flora in the crop [25]. The capacity of Lactobacillus to 
inactivate macrolides has been reported [24] and could explain the 
differences observed when Tylvalosin is deposited into the crop, in 
which the flora is almost 100% composed of Lactobacillus. 
Our finding showed that the elimination half-life t 0.5 el of Tylvalosin 
was 5.309 h. This finding was higher than reported in chickens 
(2.474 h) [6] and (1 to 1.45 h) in poultry [4]. This difference may be 
related to the changes in the chemical structure of Tylvalosin than 
tylosin, due to the addition of the isovaleryl group [26]. 
Following a single intramuscular administration of Tylvalosin (25 
mg/kg b.w.), the drug was detected in serum 5 min post 
administration 0.666 µg/ml. It was continued to increase gradually 
thereafter to reach its maximum concentration (C max) 1.446 µg/ml 
at 15 min. post-administration, this result was similar to that 
reported for rabbit after intramuscular administration of tylosin 
tartrate (0.96-1.25 µg/ml) [27] and with subcutaneous 
administration of tylosin in chickens (1.3 µg/ml) [28].  
After intramuscular administration, Tylvalosin was absorbed very 
rapidly with a T max of (0.282), whereas T max after the oral 
administration was delayed (1.293). This result was similar to 
finding obtained after subcutaneous injection of gamithromycin a 
macrolide antibiotic in chickens [29]. Tylvalosin was rapidly 
absorbed after intramuscular administration with absorption half-
life (t 0.5 ab) 0.076 h, this result was similar to that obtained with 
tylosin in chickens (0.170 h) [30]. 
Our finding showed that the elimination half-life (t 0.5 el) of Tylvalosin 
after IM injection was (0.467 h), this finding was lower than 
reported with tylosin in the calf (2.24 h), buffalo (2.40 h) and sheep 
(2.3-6 h) [31]. This difference may be attributed to the anatomical and 
physiological differences between these species as well as to the 
difference in the chemical structures of Tylvalosin. The systemic 
bioavailability of Tylvalosin after oral administration in normal turkeys 
was 33.84 %.; this result was similar to that reported with tylosin in 
chickens (30.7-34%) [16], but higher than that reported in chickens 
(25%) [13], and lower than reported in chickens (35.41-40.56 %) [21].  
 
Table 1: Mean serum concentrations of Tylvalosin (µg/ml) in turkeys following a single intravenous, intramuscular and oral 
administration of 25 mg/kg b.w. (mean±SE) 
Time of sampling (h)   Mean serum concentration of Tylvalosin after  













































 (n=10), ND: not detected 
 
Table 2: Pharmacokinetic parameters of Tylvalosin in turkeys following a single intravenous, of 25 mg/kg b.w. (mean±SE) 
Pharmacokinetic parameters  Units   Intravenous injection 
Cpo   µg/ml  63.33±5. 84  
A  µg/ml  52.74±6.03 
α  min  9.137±0.177 
t 0.5 α  h  0.076±0.0014 
B  µg/ml  10.588±1.721 
β  h-1  0.947±0.163 
t 0.5 β  h  0.788±0.107 
K12  h-1  4.03±0.373 
K21  h-1  2.33±0.338 
Kel  h-1  3.72±0.369 
Vc  L/kg  0.406±0.04 
Vd B  L/kg  2.555±0.40 
Vd area  L/kg  1.662±0.243 
Vdss  L/kg  1.155±0.183 
 Cl(B)   ml/kg/h  1.489±0.143 
AUC  µg/ml/h  17.37±1.97 
MRT  h   0.793.73±0.125 
AUMC  µg/ml/h  14.189±3.50 
(n=10) , Cp° concentration at zero time (immediately after single IV injection), A, B zero-time intercepts of the biphasic disposition curve. α, β hybrid 
rate constants representing the slopes of distribution and elimination phases, respectively. k12 first-order constant for transfer from central to the 
peripheral compartment; k21 first-order constant for transfer from peripheral to the central compartment; Kel elimination rate constant. t 0.5 α 
distribution half-life; t 0.5 β elimination half-life; Vc apparent volume of the central compartment; Vdss volume of distribution at steady state; Vd B 
volume of distribution calculated by extrapolation method; Vd area volume of distribution calculated by area method. MRT mean residence time; 
AUC area under serum concentration-time curve; AUMC area under moment curve; Cl(B) total body clearance. 
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The systemic bioavailability of Tylvalosin after intramuscular 
administration was 14.06%, this result similar to that reported with 
tylosin phosphate after oral administration in chickens (13.74%) 
and lower than that recorded for tylosin tartrate in chicken (25.8%) 
after oral administration [13] and in camels (41%) after IM 
administration [32]. The difference in the AUC may be due to the 
differences in the achieved bioavailability. 
The in-vitro protein-binding tendency of Tylvalosin in serum was 
(12.33%). This finding provides evidence that Tylvalosin was not 
extensively bound to serum protein in turkeys, and it might explain 
the high diffusion of Tylvalosin in tissues of turkeys and high value 
of the volume of distribution.  
Previous result recorded that tylosin has low binding to serum 
proteins [33, 13]. 
  
Table 3: Pharmacokinetic parameters of Tylvalosin in turkeys following a single intramuscular and oral administration of 25 mg/kg b.w. 
(mean±SE) 
Pharmacokinetic parameter Units Intramuscular Oral 
A µg/ml 2.55±0.313 0.801±0.042 
Kab h-1 9.107±0.335  2.46±0.107 
t 0.5 ab h 0.076±0.003 0.283±0.012 
B µg/ml 2.55±0.313 0.801±0.042 
Kel h-1  1.55±0.190  0.135±0.014 
t 0.5 el h 0.467±0.058  5.309±0.542 
Tmax h 0.282±0.008 1.293±0.024 
Cmax µg/ml 1.446±0.121 0.637±0.018 
AUC µg/h/ml 2.44±0.120 5.878±0.324 
MRT h 0.784±0.083 8.064±0.768 
F % 14.06±0.69 33.84±1.86  
(n=10) 
 
kab first-order absorption rate constant; Kel elimination rate 
constant; Cmax maximum serum concentration; Tmax time to peak 
serum concentration; t 0.5 ab absorption half-life; t 0.5 el elimination 
half-life; MRT mean residence time; AUC area under serum 
concentration-time curve; F fraction of drug absorbed systemically 
after oral or intramuscular administration. 
 
 
Fig. 1: Semilogarithmic plot depicting the time-course of 
tylvalocin in serum of turkeys after a single intravenous (•) 
intramuscular (▲) and oral administration (■) of 25 mg/kg b. w 
 
CONCLUSION 
These data allow concluding that Tylvalosin was highly absorbed 
and distributed to tissues and rapidly eliminated from the body of 
turkeys after oral and intramuscular administration. However, 
repeated doses are necessary to maintain Tylvalosin serum 
concentration above the MIC for most susceptible microorganisms. 
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